Showing results (151-160 of 314) with videos related to

Sort By:
Pageof 32
Plos One|November 24, 2011
Prevalence of heart failure and atrial fibrillation in minority ethnic subjects: the Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES)Paramjit S Gill, Melanie Calvert, Russell Davis, et al.
European Journal of Heart Failure|April 17, 2012
Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF studyJohn G F Cleland, Jacqueline Taylor, Nick Freemantle, et al.
European Heart Journal|November 18, 2006
The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillatorGuiqing Yao, Nick Freemantle, Melanie J Calvert, et al.
European Heart Journal|June 20, 2006
Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]John G F Cleland, Jean-Claude Daubert, Erland Erdmann, et al.
The New England Journal of Medicine|March 9, 2005
The effect of cardiac resynchronization on morbidity and mortality in heart failureJohn G F Cleland, Jean-Claude Daubert, Erland Erdmann, et al.
Diabetes, Obesity & Metabolism|February 22, 2023
iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world dataCristian Guja, János Tibor Kis, Martin Haluzík, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|February 14, 2023
Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled AnalysisMartin Haluzík, Jochen Seufert, Cristian Guja, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|September 14, 2024
Real-Life Effectiveness of iGlarLixi (Insulin Glargine 100 U/ml and Lixisenatide) in People with Type 2 Diabetes (T2D) According to Baseline HbA1c and BMIJanos T Kis, Jochen Seufert, Martin Haluzík, et al.
ERJ Open Research|June 17, 2025
External validation of the LENT and PROMISE prognostic scores for malignant pleural effusionCraig A Mounsey, Nikolaos I Kanellakis, Dinesh N Addala, et al.
Eclinicalmedicine|November 21, 2022
Use of non-selective B-blockers is safe in hospitalised decompensated cirrhosis patients and exerts a potential anti-inflammatory effect: Data from the ATTIRE trialThais Tittanegro, Louise China, Ewan Forrest, et al.
Pageof 32